Bone mineral density and body composition in Noonan's syndrome: Effects of growth hormone treatment

C. Noordam, J. Span, R. R. van Rijn, E. Gomes-Jardin, C. van Kuijk, B. J. Otten

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalJournal of Pediatric Endocrinology and Metabolism
Volume15
Issue number1
Publication statusPublished - 2002

Cite this

Noordam, C. ; Span, J. ; van Rijn, R. R. ; Gomes-Jardin, E. ; van Kuijk, C. ; Otten, B. J. / Bone mineral density and body composition in Noonan's syndrome : Effects of growth hormone treatment. In: Journal of Pediatric Endocrinology and Metabolism. 2002 ; Vol. 15, No. 1. pp. 81-87.
@article{6bd4e7e508a947e482aa852fc4098403,
title = "Bone mineral density and body composition in Noonan's syndrome: Effects of growth hormone treatment",
abstract = "We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.",
keywords = "Body composition, Bone mineral density, Growth hormone, Noonan's syndrome",
author = "C. Noordam and J. Span and {van Rijn}, {R. R.} and E. Gomes-Jardin and {van Kuijk}, C. and Otten, {B. J.}",
year = "2002",
language = "English",
volume = "15",
pages = "81--87",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH",
number = "1",

}

Bone mineral density and body composition in Noonan's syndrome : Effects of growth hormone treatment. / Noordam, C.; Span, J.; van Rijn, R. R.; Gomes-Jardin, E.; van Kuijk, C.; Otten, B. J.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 15, No. 1, 2002, p. 81-87.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Bone mineral density and body composition in Noonan's syndrome

T2 - Effects of growth hormone treatment

AU - Noordam, C.

AU - Span, J.

AU - van Rijn, R. R.

AU - Gomes-Jardin, E.

AU - van Kuijk, C.

AU - Otten, B. J.

PY - 2002

Y1 - 2002

N2 - We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.

AB - We assessed bone mineral density (BMD) and body composition in children with Noonan's syndrome (NS) before and during growth hormone (GH) treatment. Sixteen children (12 boys, 4 girls) with NS aged 5.8-14.2 (mean 10.0) years were studied for 2 years. Anthropometry, BMD measurements by radiographic absorptiometry and bioimpedance measurements (Akern-BIA 101/S) were performed at baseline and after 3, 6, 12 and 24 months. Daily GH dosage was 0.05 mg/kg. Trabecular volumetric BMD was normal; cortical BMD was in the lower normal range at baseline and slightly increased over the 2 years. Fat free mass and total body water were below normal at the start and increased significantly over the first 3 months, with a slight increment thereafter. Percentage fat mass decreased over the first 6 months and increased thereafter. These findings are comparable to the data on body composition in short normal children and girls with Turner's syndrome treated with GH.

KW - Body composition

KW - Bone mineral density

KW - Growth hormone

KW - Noonan's syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036003824&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 81

EP - 87

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 1

ER -